Health
Novartis’ New Drug Shows Strong Results Against Malaria, Offering Hope Amid Rising Resistance
Swiss pharmaceutical company Novartis has reported promising results for its experimental malaria drug GanLum, saying it will move quickly to seek regulatory approval after a successful late-stage clinical trial. The new treatment has shown strong effectiveness not only against standard malaria strains but also against drug-resistant forms of the parasite, a growing concern in Africa and other parts of the world.
The trial involved nearly 1,700 participants across 12 African countries, comparing GanLum to existing artemisinin-based combination therapy (ACT), which has been the standard treatment for the past two decades. Four weeks after treatment, 85.3 percent of patients who received GanLum had no symptoms or detectable parasites, compared with 82.1 percent in the group that received standard care. Novartis said this translates to a cure rate of 99.2 percent for GanLum versus 96.7 percent for existing therapies.
Dr. Abdoulaye Djimdé, a professor of parasitology and mycology at the University of Science, Techniques and Technologies of Bamako, Mali, described the results as potentially “the biggest advance in malaria treatment for decades.” He noted that “drug resistance is a growing threat to Africa, so new treatment options can’t come a moment too soon.”
Malaria remains one of the world’s most serious infectious diseases. According to the World Health Organization (WHO), there were around 263 million malaria cases and 597,000 deaths globally in 2023, with Africa accounting for the vast majority. Children under five represent about three-quarters of all malaria deaths on the continent.
Current treatments rely mainly on ACT, which combines artemisinin with other drugs. However, resistance to artemisinin has begun to emerge in several African countries, including Rwanda, Uganda, and Eritrea, raising fears that progress against the disease could stall. GanLum’s formula uses two different compounds that attack the malaria parasite through separate biological mechanisms, helping it remain effective even against resistant strains.
Dr. Shreeram Aradhye, president of development and chief medical officer at Novartis, said the new treatment “has the potential to both treat the disease and block transmission.” He added that the company plans to move “as quickly as possible” to submit GanLum for regulatory approval.
The trial focused on patients with acute, uncomplicated malaria caused by Plasmodium falciparum, the most deadly and widespread malaria parasite in Africa. The research was funded partly by the European Union, Germany, and the United Kingdom, and the results were presented this week at a scientific meeting.
Dr. Alena Pance, a senior genetics lecturer at the University of Hertfordshire in the United Kingdom who was not involved in the study, called the findings “really encouraging,” though she urged further testing on severe and cerebral malaria as well as other parasite species.
If approved, GanLum could mark a major milestone in the global fight against malaria, providing a new tool to counter the rise of resistance and potentially saving hundreds of thousands of lives each year.
Health
Genetic Differences May Shape Effectiveness of Popular Weight-Loss Drugs, Study Finds
Health
Seven-Day Meditation Retreat Linked to Measurable Changes in Brain and Body, Study Finds
Health
Uzbekistan to Launch Nationwide State Medical Insurance System in 2026
Uzbekistan will begin introducing a nationwide state medical insurance system from 2026, part of a broader overhaul of the country’s healthcare financing and service delivery. The reform will introduce digital referrals, a national health insurance fund, and a guaranteed package of essential medical services funded through the state budget. Officials say the changes aim to improve efficiency, expand access, and reduce informal payments.
“State health insurance is a social protection system designed to guarantee access to quality healthcare services,” said Zokhid Ermatov, executive director of the State Health Insurance Fund.
Discussions about state medical insurance in Uzbekistan began in 2017, but implementing such a system required years of preparation. The State Health Insurance Fund was formally established in December 2020, and pilot programmes launched in the Syrdarya region in 2021 tested new financing mechanisms, regulatory frameworks, and digital health systems. In November 2025, the Cabinet of Ministers approved regulations governing how medical care funded through the state budget will be provided in public and private medical institutions, with the rules set to come into force on January 1, 2026.
At the centre of the new model is stronger primary healthcare. Patients will first visit their assigned family clinic, where doctors provide consultations, prescribe tests, and determine whether specialist care is needed. If necessary, patients will receive an electronic referral to hospitals or specialists. Emergency and urgent care will remain available without referrals.
The reform introduces a patient-centred financing model, where healthcare providers are paid by the State Health Insurance Fund based on services delivered. Primary healthcare will be funded through capitation payments, while hospital treatment will follow case-based payments, a structure designed to improve efficiency and treatment outcomes.
A fully digital referral system will allow patients to choose hospitals from a list of institutions contracted with the State Health Insurance Fund using a government portal or mobile app. Referrals will remain valid for 60 days, and waiting lists and hospitalisations will be managed through a unified electronic health information system.
The insurance system guarantees essential healthcare services, including family doctor consultations, diagnostic tests, outpatient treatment, preventive screening, some medicines, hospital care, and certain rehabilitation services. Patients will not be charged additional fees for services included in the approved package.
Funding for the program will come primarily from the state budget, ensuring citizens do not pay direct insurance contributions. Priority access will be given to socially vulnerable groups, including children with disabilities, orphans, pensioners, pregnant women, unemployed citizens, and low-income families. The State Health Insurance Fund will allocate resources across regions to strengthen medical services and reduce inequalities.
International organisations have praised Uzbekistan’s approach, noting that general tax financing and universal coverage can improve financial protection and ensure predictable healthcare funding. Jessika Yin, Health Policy Adviser at the World Health Organization in Uzbekistan, said the reforms align with global trends toward universal health coverage.
If implemented successfully, Uzbekistan’s state medical insurance system could represent a major step toward universal healthcare, ensuring that people receive care without facing financial hardship.
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Home Improvement1 year agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
